Besides, targeting signaling pathways is possible, for instance, BBI-608 drug targeting STAT3 could be used for advanced CRC resistant to standard therapeutics or in mixture with Paclitaxel for advanced GC (2, 97). Here, STAT3 is linked to colorectal carcinoma.